Your Online Resource for BioProcess Technology
 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 
Forward
Techno-Blast
Thursday, October 26, 2017  |  Volume 9 / Number 22  |  A Production of the BioProcessing Journal
Liquid Handling
ISBioTech 5th Fall Meeting
Career Development
ISPE
Annual Meeting & Expo
October 29–November 1, 2017
San Diego, California USA
4th International Workshop on Statistical and Data Management Approaches for Biotechnology
Drug Development
October 30–
November 1, 2017
Rockville, Maryland USA
Phacilitate
Cell & Gene Therapy World
&
Immuno-Oncology Frontiers World
January 23–25, 2018
Miami, Florida USA
ACHEMA
ACHEMA
June 11–15, 2018
Frankfurt am Main, Germany
MSS 2018
8th Monolith Summer School and Symposium
June 15–20, 2018
Portorož, Slovenia
Suggested Reading
Opinion Editorial
POP Talk: Prepare, Organize, Present
By Tom Kost, PhD, DTM (Distinguished Toastmaster)
Products & Services
Single Cell Analysis System

TTP Plc (TTP) and Sphere Fluidics have launched the Cyto-Mine® Single Cell Analysis System to automate single cell analysis, sorting, imaging, and dispensing to boost throughput and sensitivity throughout the biopharmaceutical discovery process.

Cyto-Mine® Single Cell Analysis System
The proprietary algorithm software and optical hardware from Sphere Fluidics enables single cell compartmentalisation and fluorescence-assisted sorting. The instrument is compatible with the Cyto-Cartridge®, a disposable microfluidic biochip that integrates Sphere Fluidics’ core technology in picodroplet generation and sorting for cellular applications with TTP’s dispensing technology. The Cyto-Cartridge allows single cells of interest to be dispensed into individual wells of a microtitre plate for biopharma discovery, cell line development, and monoclonality assurance. This enables a step change in throughput for biopharma applications.

The GLP-compliant system fits in a standard biological safety cabinet and can deliver up to 10 million tests in a single day. For more information, please visit spherefluidics.com.

New Filters Provide Twice the Capacity Using Fully Synthetic Materials

MilliporeSigma has announced Millistak+® HC Pro, the first portfolio of high-capacity, fully synthetic depth filters for non-treated Chinese hamster ovary (CHO) harvest clarification and downstream filtration applications. Millistak+ HC Pro filter media provide a clean and consistent depth filtration process. Made with purely synthetic materials, Millistak+ HC Pro filters eliminate naturally derived components from the clarification process, offering increased productivity with lower flushing recommendations. As an added benefit, the synthetic media shows higher levels of host cell protein (HCP) clearance compared with traditional depth filters.

Millistak+® HC Pro
Millistak+ HC Pro filters reduce total organic carbon (TOC) extractables and pre-use flush volume recommendations by 50 percent. The synthetic nature of the filter media eliminates beta glucans that interfere with limulus amoebocyte lysate testing for bacterial endotoxins. The flexible, modular filters are available in the disposable pod format for ease of use, exist in three media grades for primary and secondary clarification, as well as downstream filtration applications, and offer scalability from the bench to commercial manufacturing scale. For more information, please visit emdmillipore.com.
GMP Manufacturing Infrastructure and Cleanroom Capacity
Expands to Support Clients through Commercial Stage

Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS) has announced the planned expansion of its PCT service platform through the addition of GMP manufacturing infrastructure and cleanroom capacity in Allendale, New Jersey. The expansion includes the addition of 49,700 square feet in a new facility (its “75 Commerce facility”) as well as upgrades to the existing facility at 4 Pearl Court, allowing seamless support and manufacturing services for clinical and commercial applications.

The 75 Commerce facility will house additional Grade B/ISO 7 controlled environment rooms, HCATS’ Center for Innovation and Engineering, manufacturing development labs, quality control and microbiology labs, warehousing, and executive offices. Construction and facility validation is expected to be complete by the end of 2018. The existing 4 Pearl Court 30,000 square foot manufacturing facility, housing six clean rooms, will be renovated for improved process flow and commercial infrastructure with completion of these upgrades expected by the end of April 2018, with facility validation by the end of June 2018.

All locations will share the same global PCT service platform for quality and information systems, manufacturing operations, and technology transfer protocols. For more information, please visit pctcelltherapy.com.

Career Development
CASSS
CMC Strategy Forum Japan
December 4–5, 2017
Tokyo, Japan
CMC Strategy Forum Winter
January 29, 2018
Washington, DC USA
WCBP
January 30–February 1, 2018
Washington, DC USA
AAPS
Annual Meeting & Exposition
November 12–15, 2017
San Diego, California USA
SLAS
SLAS International Conference & Exposition
February 3–7, 2018
San Diego, California USA
PREP
PREP 2018—31st International Symposium on Preparative and Process Chromatography
July 8–11, 2018
Baltimore, Maryland USA
ISBioTech 8th Spring Meeting
Advertising: Request a media kit!
Banner description: Confocal fluorescence image of Indian Muntjac deer skin fibroblast cells.
Image provided by Michael W. Davidson, National High Magnetic Field Laboratory (www.microscopy.fsu.edu), The Florida State University, Tallahassee
Did a colleague forward this to you? Subscribe here. While we'd hate to see you go, you can unsubscribe instantly.

[[tracking_beacon]]

IABS FDA